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The pathogenesis of autoimmune diseases includes a combination of genetic factors and environmental exposures including
infectious agents. Infectious triggers are commonly indicated as being involved in the induction of autoimmune disease, with
Epstein-Barr virus (EBV) being implicated in several autoimmune disorders. EBV is appealing in the pathogenesis of autoimmune
disease, due to its high prevalence worldwide, its persistency throughout life in the host’s B lymphocytes, and its ability to
alter the host’s immune response and to inhibit apoptosis. However, the evidence in support of EBV in the pathogenesis varies
among diseases. Autoimmune liver diseases (AiLDs), including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and
primary sclerosing cholangitis (PSC), have a potential causative link with EBV. The data surrounding EBV and AiLD are scarce.
The lack of evidence surrounding EBV in AiLD may also be reﬂective of the rarity of these conditions. EBV infection has also been
linkedtootherautoimmuneconditions,whichareoftenfoundtobeconcomitantwithAiLD.Thispaperwillcriticallyexaminethe
literature surrounding the link between EBV infection and AiLD development. The current evidence is far from being conclusive
of the theory of a link between EBV and AiLD.
1.Introduction
Severalviruseshavebeenconsideredtobetriggersofautoim-
munity and overt autoimmune disease [1–6]. Amongst
those, Epstein-Barr virus (EBV), which is the cause of
infectious mononucleosis, is unique in a sense as it has
been implicated in the induction of multiple autoimmune
diseases [7, 8]. These include systemic lupus erythematosus
(SLE), multiple sclerosis (MS), autoimmune thyroiditis
(AT), rheumatoid arthritis (RA), inﬂammatory bowel dis-
eases (IBD), insulin-dependent diabetes mellitus (IDDM),
Sj¨ ogren’s syndrome (SjS), systemic sclerosis (SSc), myasthe-
nia gravis, and autoimmune liver diseases (AiLD) [7–20]. In
fact, there are very few autoimmune diseases in which EBV
has not been considered as a potential trigger of immune-
mediated destruction. While in some of these diseases there
is growing evidence in support of the link between EBV and
autoimmunity, the link is not as strong as in others, and the
pathogenic involvement of EBV is a matter of heated debate.
This paper will discuss the clinical and experimental
data investigating the role of EBV in the pathogenesis of
AiLD.Asthesediseasesfrequentlyco-occurwithextrahepatic
autoimmune diseases, we also discuss EBV’s involvement
in the pathogenesis of autoimmune manifestations seen in
patients with AiLDs, as this topic has not been discussed
previously in great detail. AiLDs include a heterogeneous
group of disorders that aﬀect the hepatocytes as in the case
of autoimmune hepatitis (AIH) and the cholangiocytes as2 Advances in Virology
Table 1: Evidence is support and against a role of Epstein-Barr virus (EBV) in autoimmune liver disease (AiLD). Evidence in support of
EBV in the pathogenesis of autoimmune hepatitis (AIH) is largely based around case reports noting the development of AIH following EBV
infection. In contrast, studies on EBV and primary biliary cirrhosis (PBC) have been based on the detection of EBV genetic material in PBC
patients. As well, molecular mimicry between EBV and self-proteins has also been indicated, with mixed results. Although convincing, it
should be noted that EBV is ubiquitous in a large percentage of the population, and thus cannot be causally linked. Evidence linking EBV
with PSC is weak, based only on indirect evidence of the role of EBV in the pathogenesis of ulcerative colitis, which is present in many
patients with primary sclerosing cholangitis (PSC).
Disease Evidence in support of EBV Evidence against EBV
Autoimmune
hepatitis (AIH)
(i) Several case reports indicating the development
of AIH following EBV infection
(i) The high prevalence of EBV would indicate a
higher development of AIH post-EBV infection,
which is not the case
(ii) Strong EBV links with autoimmune diseases,
such as systemic lupus erythematosus (SLE) that are
not commonly concomitant with AIH
(iii) A CYP2D6259–271 mimicking peptide from
BVRF1 EBV is totally unreactive in
anti-CYP2D6254–271 positive patients with AIH-2
(ii) Serological evidence of EBV infection in AIH
patients
(iii) Strong link between EBV and rheumatoid
arthritis, autoimmune thyroid, and Sj¨ ogrens
syndrome, which are often concomitant in patients
with AIH or other AiLDs
(iv) Molecular mimicry and immunological
cross-reactivity implicating an EBNA EBV epitope
and the immunodominant CYP2D6259–271 epitope is
demonstrated in patients with AIH-2
Primary biliary
cirrhosis (PBC)
(i) Increased EBV DNA found in peripheral blood
mononuclear cells, liver and saliva of PBC patients
(ii) Increased EBV early antigen titers in PBC (i) Increased EBV early antigen titers also found in
other autoimmune diseases
(iii) Strong link between EBV and rheumatoid
arthritis, autoimmune thyroid, and Sjogrens
syndrome, which are often concomitant in AiLD
(ii) Strong EBV links with autoimmune diseases,
such as SLE, that are not commonly concomitant
with PBC




(i) Increased EBV infected B lymphocytes in the
intestinal mucosa of ulcerative colitis patients (which
is often concomitant in PSC)
(i) No direct evidence or case reports linking EBV to
PSC
in the case of primary biliary cirrhosis (PBC) and primary
sclerosing cholangitis (PSC). The evidence for EBV as a
causative agent varies from one autoimmune liver disease to
the other (Table 1). However, there does not appear to be any
conclusive evidence linking EBV with the induction of AiLD.
2. GeneralAspects of Autoimmunity
It is generally supported by most researchers that the vast
majority of autoimmune diseases develop from the close
interaction of genes, epigenetic factors, and “multiple hits”
from environmental agents [21, 22]. More than 100 types of
autoimmune disease have been described so far. Individual
autoimmune diseases appear rare, but it is estimated that
∼5–20% of the North American population has at least one
autoimmune disease [23].
The aetiology of autoimmune disease is complex, involv-
ing immunological, genetic, and environmental factors. The
extent to which these factors are implicated diﬀers from one
disease to the next. Monozygotic concordance rates below
50% support the notion that environment as well as genetics
are closely involved [24–28]. As well, epidemiological studies
on populations with the same or similar genetic or ethnic
background living under diﬀerent conditions or migrating
to diﬀerent places have reported diﬀerent incidence rates
of autoimmune disease. The development of autoimmune
disease as a result of exposure to these factors can be medi-
ated by a variety of mechanisms such as T-cell dysregulation,
nonspeciﬁc activation of the immune system, release of
cryptic antigens, altered structure or expression of autoanti-
gens, antiapoptotic eﬀects on autoreactive cells, molecular
mimicry and immunological cross-reactivity, to name a few
[1, 29–33]. In recent years, large genetic studies known as
genomewide association studies (GWASs) have discovered
severalgeneassociationswithvariousautoimmunedisorders
[34].AlthoughGWASshavebeenpivotalinrevealingspeciﬁc
genetic inﬂuences, exposures to infections are also likely to
participate in the breakdown of immunological tolerance
and the development of full-blown autoimmune disease
[34, 35]. In fact, some of the genes that confer susceptibility
to autoimmunity may also inﬂuence the penetrance of
infectious agents and the appearance of recurrent infections
with viruses or microbes implicated in the induction of
autoimmunity. Epidemiological studies have helped us to
identify infectious and noninfectious environmental agents
(such as xenobiotics, chemical compounds, radiation, vac-
cines) [35]. The prevailing notion from the GWAS is that
multiple genes are needed to induce autoimmunity [34].
Epidemiological, clinical, and experimental studies have
also revealed that several infectious triggers are most likelyAdvances in Virology 3
needed to provoke immune-mediated processes that lead to
autoimmunity. The additive eﬀects of these agents and their
interplay with susceptible genes remain poorly understood.
In fact, on several occasions the same infectious agents
that induce autoimmunity may also be responsible for the
abrogation of autoimmune phenomena in another clinical
setting.
Against this background which suggests that the induc-
tion of autoimmune disease is a complex, multifactorial
process involving a plethora of genetic, infectious, and en-
vironmental agents working in concert, there are studies to
suggest that a single virus may possess a unique property to
induce generalised autoimmunity. These studies single out
EBV as the most likely candidate with such properties [7, 8,
36].
T h ei d e a lv i r u sw h i c hc a ni n d u c ea u t o i m m u n i t yw o u l d
need to explain disease-speciﬁc features frequently seen in
themajorityofautoimmunedisorders.Forexample,involve-
ment of this virus would need to provide clues as to why
some autoimmune diseases run a subclinical course of sev-
eral years, with diagnosis of the disease being made after the
target organ has been damaged. Such cases are found in a
signiﬁcant proportion of patients with AiLD, AT, and IDDM,
for example. Viral-induced autoimmunity will also need to
explain the relapsing-remitting course of MS, RA, ulcerative
colitis, PSC and AIH [1, 4–6]. As most autoimmune diseases
are characterised by non-organ and organ-speciﬁc autoanti-
bodies, the virus in question will need to be able to provoke
the induction of a wide variety of autoantibody speciﬁcities
[2]. It would also need to explain the female preponderance
of most autoimmune diseases and the tendency of these
diseases to be unmasked during the postmenopausal or
postpartum period [21].
3. EBV asa Trigger of Autoimmunity
EBV (also known as human herpes virus 4) infection is
widespread, with 98% of the world’s population being
infected [8] .I t sg e n o m ei sc o m p o s e do fa1 7 2 k bd o u b l e
strand of DNA [8]. Primary infection with EBV is followed
by viral replication in nasopharyngeal epithelia and B cells,
followed by a latent stage in B cells [8]. There are several
features of EBV which make it an appealing culprit in the
pathogenesisofautoimmunedisease[7,8,36].Theseinclude
its high prevalence worldwide, its persistency throughout life
in the host, its ability to alter the immune system of the host
and to inhibit apoptosis, as well as the fact that infection
precedes the onset of disease symptoms [8].
Amongstthose,themostintriguingcharacteristicofEBV
is its ability to infect, activate, and latently persist in B lym-
phocytes. In vitro systems of resting B cells infected with EBV
showed that these cells proliferate without the need for “T-
cell-dependent help” [37]. Also, in vitro studies have shown
thatEBV-transformedBlymphocytescaninduceproduction
of monoclonal antibodies targeting various organ-speciﬁc
autoantigens [38]. Most of the EBV-infected proliferating B
cells act as targets of virus-speciﬁc CD8+ T cells and are
eliminatedfromthecirculation,howevermemoryBcellscan
persist for life in infected individuals [37].
MoststudiesimplicatingEBVasatriggerofautoimmune
diseases are based on ﬁndings indicating high titers of
EBV-speciﬁc antibodies in patients compared to controls
[3]. Additionally, a higher proportion of EBV-infected cells
with elevated EBV loads are found in peripheral blood
lymphocytes compared to other pathological or normal
controls. Diseases with an increased risk of lymphoma like
primary SjS, RA, and SLE are considered to be more prone
to be induced by EBV compared to others with a risk of
lymphoma comparable to that of the control population.
4.EBVandAIH
AIH is an inﬂammatory liver disease primarily aﬀecting
women and is characterised by elevated transaminase levels,
thepresenceofspeciﬁcautoantibodies,raisedIgG,andinter-
facehepatitisonhistology[39–44].Althoughtheaetiopatho-
genesisofAIHisunc lear ,sev eralaut oimm unepath wa ysha v e
beenproposedwhicharelargelybasedonautoreactiveCD4+
T lymphocytes recognizing a liver-speciﬁc autoantigen [45–
47].
AIH can be divided into AIH type 1 or type 2, based
largely on distinct autoantibody proﬁles [48, 49]. AIH type
1a ﬀects all ages while AIH type 2 is practically limited
to the paediatric population. Antinuclear antibody (ANA)
and smooth muscle antibody (SMA) characterize type 1,
while antibodies to liver kidney microsomal antigen type 1
(anti-LKM1) and anti-liver cytosol type 1 antibodies (anti-
LC1) are characteristics of type 2 [39, 41, 44, 48, 49].
Other autoantibodies include antisoluble liver antigen/liver
pancreas antibody (SLA/LP) and antibodies against the
asialoglycoprotein receptor (ASGP-R) [39, 41, 44, 48, 49].
Conventional treatments of AIH include immunosup-
pression with prednisolone, with or without azathioprine
[39, 40, 50]. Most patients show a good response to treat-
ment, which should be initiated soon after diagnosis. Left
untreated, AIH progresses to cirrhosis and liver failure
requiringlivertransplantation[39,40,50].Theprevalenceof
AIH is estimated to be 1.9 to 20 per 100,000, but this is likely
underestimated [39, 40, 50]. The diseases is characterised by
a female predominance with 75% of patients being female
andafamilyhistoryofautoimmunedisorderswhichisfound
in 40% of cases [39–44].
AIH may present acutely in approximately 40% of cases
and may resemble acute viral hepatitis [39–44, 51]. The
remaining cases may have an insidious onset presenting
with less acute illness, characterized by relapsing jaundice,
fatigue and weight loss over months to years [39–44, 51].
Other causes of chronic liver disease such as viral hepatitides,
Wilson’s disease, drug-induced hepatitis, alcoholic hepatitis,
as well as other infrequent causes of chronic liver disease
must be excluded [39–44, 51]. The aetiopathogenesis of AIH
is poorly understood, but there is some evidence to suggest
that a numerical and functional impairment of T-regulatory
cells may be involved [45, 52–55]. In addition, a variety
of genetic and environmental factors are involved in the
development of the disease, including viruses. AIH following
an acute viral infection has been strongly associated with
hepatitis A virus (HAV) and hepatitis B virus (HBV), but4 Advances in Virology
several cases report the development of AIH following EBV
infection [20, 56–58]. A prospective study conducted by
Vento et al. followed the relatives of 13 AIH patients, in order
to determine whether these relatives developed serological
or clinical evidence of AIH [20]. Infectious mononucleosis
developed in 7 of the 13 patients following EBV infection,
with AIH developing within 4 months of this infection in 2
of the 7 individuals [20].
Ac a s er e p o r tb yK o j i m ae ta l .[ 57] also describes the
association of AIH with EBV infection. That case involved
a 73-year-old man presenting with fever, lymphadenopathy,
granulocytopenia, thrombocytopenia, ascites, pleural eﬀu-
sion, liver injury, and a skin rash [57]. Antibodies to EBV
were detected, and circulating lymphocytes were positive for
the EBV genome [57]. ANAs were also present, and the
histological features of a liver biopsy resembled those seen
in AIH [57]. A paediatric case of a 5-year-old with AIH-like
histopathological features induced after EBV infection has
also been reported [58]. These case reports are suggestive of
EBVinducingpaediatricaswellasadultformsofAIHtype1,
but it still remains unclear whether there is a true link or it is
due to the rarity of these cases and the lack of direct evidence
associatingthetwoconditions.Duetotheuniversalexposure
to EBV infection, an increased number of studies reporting
induction of EBV-induced AIH would be expected, but this
appears not to be the case.
One group reports the case of fatal chronic active EBV
infection mimicking AIH [59]. That 22-year-old female
presented with pyrexia, pancytopenia, and liver dysfunction.
Her previous medical history included a diagnosis of AIH
six years previously, after presenting with liver dysfunction,
low-grade fever, and mild hepatosplenomegaly [59]. Liver
biopsy on admission indicated chronic active EBV infection,
including in situ hybridization which demonstrated lympho-
cytes and Kupﬀer cells positive for EBV-encoded small RNA-
1[ 59]. Serological markers for EBV were also raised. She
was commenced on prednisolone and cyclosporine [59]. Ten
months after diagnosis, the patient died due to liver failure
and virus-associated hemophagocytosis [59]. Retrospective
examination of serum samples taken at the previous diag-
nosis of AIH showed high titres of EBV antibodies and EBV-
DNAwasdetectedbyPCR[59].Thoseauthorshighlight that
hepatic involvement of chronic active EBV infection should
be included in the list of diﬀerential diagnoses, in cases of
liver dysfunction with clinical and biochemical features of
AIH [59]. In contrast is a case report by Nakajima et al. [60]
which describes the case of a ten-year-old female, admitted
due to cholestasis and elevated liver enzymes for 2 months.
EBV-DNA was found to be raised in the peripheral blood
mononuclear cells [60]. She had hypergammaglobulinemia
and was positive for ANA and SMA [60]. Liver histology
demonstrated interface hepatitis, dense mononuclear cell
inﬁltrates, and mild ﬁbrosis, but was negative for EBV by
in situ hybridization [60]. Those authors highlight that
liver histology was essential to diﬀerentiate AIH from EBV
hepatitis [60]. Another case of EBV as a trigger of AIH has
been reported by Cabibi et al. [61]. A 31-year old male was
admitted with jaundice, generalised fatigue, and abnormal
liver biochemistry tests [61]. Anti-HAV, anti-HBV, and
anti-HCV were negative, as were ANA, SMA, and AMA
[61]. Antibodies to hepatitis E were positive, a diagnosis
of acute hepatitis type E was made, and the patient’s
condition progressively improved [61]. Over one year later,
the patient had markedly raised aminotransferase and a
relative lymphocytosis [61]. Anti-VCA/EBV IgM was found
to be positive, but all other viral markers and autoantibodies
were negative [61]. ANA became positive several months
later, with ANA-HEp2 being detected at a titre of 1:2560
with a homogeneous pattern, which is speciﬁc for AIH. IgG
anti-VCA/EBV and EBNA/EBV IgG were positive; however,
EBV-DNAwasnegativeinperipheralmononuclearcells[61].
Liver histology demonstrated chronic hepatitis, which was
consistent with AIH [61]. The patient was commenced on
methylprednisoloneandeventuallyazathioprine,whichwere
both stopped when liver biochemistry returned to normal
[61].
Apart from the previous case reports, no comprehensive
studies link EBV infection with the development of AIH.
As well, the potential mechanisms that may be involved in
pathogenic process of AIH following EBV infection, such as
molecular mimicry, have not been explored extensively. At
best, it can be stated that EBV induced AIH in individual
cases, but overall, there is no evidence linking EBV with AIH.
5.EBVandPBC
PBC is a chronic cholestatic liver disease characterized by
immune-mediated destruction of the small intrahepatic bile
ducts [62–64]. The prevalence of PBC varies from 28 to
402 per million and appears to be rising [65–68]. The
disease mostly aﬀects middle-aged women [65]. High-
titer serum antimitochondrial autoantibodies (AMAs) are
pathognomonicforPBC[48,62–64,69–78],anditspresence
in asymptomatic patients is believed to be predictive of
eventual disease development [79]. Approximately 30% of
patients have PBC-speciﬁc ANA [48, 49, 70, 72, 74, 77, 80–
82]. ANA may be present in AMA negative PBC patients, in
addition to asymptomatic individuals and family members
of PBC patients [83–89]. Some studies suggested that pa-
tients with PBC-speciﬁc ANA have a poorer prognosis [83,
86–98].
Presenting symptoms are often nonspeciﬁc such as
pruritus and/or fatigue or can be more severe with jaun-
dice and portal hypertension [62–64]. Most asymptomatic
patients are diagnosed incidentally [99, 100]. The diagnosis
of PBC is based on elevated alkaline phosphatase (ALP), the
presence of serum AMA (titre ≥1:40), and characteristic
liver histology [62–64, 101]. Medical treatment for PBC
is with ursodeoxycholic acid (UDCA), which has greatly
improved the life expectancy and quality of life of PBC
patients [102, 103].
The pathogenesis of PBC is unclear but experimental
and clinical data suggest that the disease is autoimmune in
nature [104, 105]. This includes the presence of autoreactive
T and B cells against speciﬁc antigens in the peripheral blood
and the inﬂamed liver tissue of PBC patients and high-titre
serum autoantibodies characteristic of the disease [69, 75,Advances in Virology 5
105–114]. There is also evidence in support of infectious
agents and xenobiotics mimicking the major autoantigen in
PBC, PDC-E2, can induce loss of immunological tolerance
and biliary epithelial-speciﬁc pathology, leading to the
destruction of the bile ducts [22, 115–117].
Some studies have found an association between PBC
and EBV infection [118]. Morshed et al. [119] obtained
peripheral blood mononuclear cells (PBMC), liver tissue,
and saliva (see the following) from PBC patients and
subjected them to PCR for the detection of viral sequences.
Increased EBV-DNA was found in 61% of PBMC, compared
to 19% in autoimmune hepatitis, 14% in patients with liver
cirrhosis of various causes, and 11% in healthy controls
[119].Liverandsalivarysamplesalsoshowedincreasedlevels
of EBV-DNA in PBC patients compared to pathological
and healthy controls [119]. A study by Barzilai et al. [3]
examined1595serumsamplesfrom23autoimmunediseases
and screened these for EBV and CMV infection. Sixty nine
samples were from patients with PBC [3]. Increased EBV
early antigen IgG titres were noted to be raised in PBC
patients compared to normal controls [3]. However, this
was not speciﬁc for PBC, as other diseases such as SLE,
RA, antiphospholipid syndrome, MS, polymyositis, SSc, SjS,
giant cell arthritis, Churg-Strauss vasculitis, and cryoglob-
ulinaemia were also characterized by increased EBV early
antigen IgG titres [3].
Much like AIH, there is no evidence conclusively linking
PBCandEBV.ThehigherprevalenceofEBVisnotspeciﬁcto
PBCbutappearstobeacharacteristicofautoimmunedisease
in general. This must be taken into account when examining
the prevalence of EBV in autoimmune diseases that are and
those that are not concomitant with PBC. Relatively limited
data are available which may suggest a role for molecular
mimicry as a potential mechanism of EBV-induced PBC (see
the following).
6.EBVandPSC
Data on the association of EBV with PSC are scarce. PSC
is a chronic progressive cholestatic disease, characterized
by immune-mediated destruction of the biliary epithelial
cells leading to ﬁbrosis and biliary cirrhosis. The reported
prevalence of PSC varies amongst studies but has been
estimated at 10 per 100,000 in Northern European popula-
tions. In their great majority, patients with PSC are young
males. This condition is associated with an increased risk
for cholangiocarcinoma and concurrence of inﬂammatory
bowel disease. The diagnosis of the disease is largely based
on endoscopic cholangiography and/or magnetic resonance
imaging and to a lesser extent on biochemical indices
of cholestasis and disease-related immunological proﬁling
which mainly includes perinuclear antineutrophilic antibod-
ies (p-ANCA). As for PBC, pharmaceutical management of
PSC includes administration of ursodeoxycholic acid. This
regimen, however, does not improve survival and curative
treatment consists of liver transplantation. In the absence
of cholangiocarcinoma, most patients with PSC who are
transplanted have excellent rates of survival.
Though there is no direct evidence of involvement of
EBV in PSC, there are studies to implicate EBV with UC with
or without concurrent PSC. Lidar et al. [120]i n v e s t i g a t e d
antibody serology against various infectious agents and
compared their titres in patients with IBD compared to
healthy controls. Antibody titres against EBV did not diﬀer
between UC and CD or between IBD and healthy controls
[120]. However, an increase number of EBV-infected B
lymphocytes in intestinal mucosal samples from patients
with ulcerative colitis compared to healthy controls have
been reported [121, 122]. It is not clear, however, how many
of the UC patients with increased number of EBV-infected
B lymphocytes had coexistent PSC [122]. To date, there does
not appear to be strong or direct evidence linking EBV and
PSC. It is not clear as to whether an association between UC




It appears that in contrast to other autoimmune diseases, the
evidence linking EBV with liver autoimmunity is not strong.
There are several reasons why this may be. For example, if
EBV was a predominant trigger of AiLD, we would expect
to see EBV-related extrahepatic autoimmune diseases in a
large proportion of AiLD patients. This does not appear
to be the case for MS and SLE which have been linked
with EBV but are infrequently found in AIH and PBC.
However, other extrahepatic autoimmune diseases such as
autoimmune thyroid disease (AiTD), SjS, and RA linked to
EBV do appear as concomitant autoimmune diseases in a
signiﬁcant proportion of patients with AiLD.
AiTD and SjS are two of the most common concomitant
autoimmunediseasestoaﬀectpatientswithAiLD.Ithasbeen
demonstrated that increased levels of anti-EBV antibodies
are present in the sera of patients with AiTD and SjS [19,
123, 124]. EBV appears to have a role in the pathogen-
esis of thyrotoxicosis, which may occur immediately after
infectiousmononucleosis,andautoimmunehypothyroidism
can develop from acute EBV infection [125]. As well, EBV-
infected B cells may play a role in the development of B-cell
lymphoma in the thyroids of patients with AiTD [126]. As
mentioned, saliva samples from patients with PBC have been
shown to have high titres of EBV [119]. This is of interest
given that increased EBV shedding from the oropharynx
has been observed in SjS patients [124], and SjS or Sicca
symptomatologyisfrequentlyobservedinpatientswithPBC.
RA is also commonly found in patients with AiLD, and
EBV infection also appears to be a feature of RA. Increased
anti-EBV antibodies have been found in the sera of RA
patients [127], and another study has found a ten-fold
increase of EBV-DNA in the peripheral blood mononuclear
cells of RA patients compared to normal controls [128].
There remains, however, some controversy as to the role
of EBV in the pathogenesis of RA. Using highly sensitive
in situ hybridization techniques to detect EBV-encoded
small nuclear RNAs (EBERs) in biopsy samples of synovial6 Advances in Virology
Table 2: Regional amino acid similarity between human cytochrome p450 IID6 (CYP2D6)257–271 (the immunodominant epitope of anti-
liver kidney microsomal antibodies type 1 in patients with autoimmune hepatitis type 2, and viral sequences originated from hepatitis C,
herpes virus 1 (HSV-1), and Ebstein-Barr virus (EBV)). Amino acids (aa) in single letter code. Identical amino acids between human and
viral sequences are indicated in bold.
Species Protein Code
Hepatitis C virus (HCV) Non structural protein 5B NS5B P P GD PP QPEYDL
Hepatitis C virus (HCV) Envelope 1 E1 I T G HRMA W DMMM
Human Cytochrome P450IID6 CYP2D6 aa254 L T E H R M T W D P A Q P P R D L 271
Herpes simplex virus type 1
(HSV-1) Immediate early 175kDa IE175 L S P RPPAQPPRR R
Epstein-Barr virus (EBV) Nuclear protein EBNA EBNA P P P AA PAQPPPG V
Epstein-Barr virus (EBV) Virion protein BVRF1 UL25 HVL I D PARLPRD T
membranesofRApatients,Niedobiteketal.[129]c oncluded
that there was insuﬃcient evidence to support the role of
EBVinthepathogenesisofRA.However,19%oftheircohort
of 37 RA patients did have EBERs, which were not found in
any of the controls from patients with non-RA joint disease
[129]. EBERs were expressed by B cells and plasma cells
[129]. Finally, EBV-speciﬁc CD8+ T cells are abundant in the
inﬂamed joints of RA patients, although this is also found in
CMV-infected joints [130].
8. The Role of MolecularMimicrybetween
EBVandSelfinAIH
The mechanisms by which microbial agents may induce
autoimmune disease are currently unknown, although
molecular mimicry between microbial and self-peptides has
been indicated [56, 83–85, 106, 131–135]. Several studies
haveprovidedevidenceforTcellorantibody cross-reactivity
b e t w e e nE B Va n ds e l f - a n t i g e n s[ 136–140]. This includes
myelin basic protein in MS [136, 139] ,L aa n t i g e ni nS j S
[137], SmD in SLE [138], and MHC-derived peptides in
oligoarticular juvenile idiopathic arthritis [140].
As anti-LKM-1 antibodies of patients with type 2 AIH
recognize a short epitopic region on CYP2D6 spanning
amino acids 254–271, attempts have been made to identify
viral triggers that could initiate virus/self-cross-reactive
immune responses. Following original reports demonstrat-
ing amino acid similarities between CYP2D6254−271,H C V ,
and HSV-1 [141, 142], researchers from King’s College Lon-
don identiﬁed additional mimics originating from human
adenovirus, human cytomegalovirus, and EBV [135, 143].
The CYP2D6259−271 mimicking sequences from EBV
(Table 2) originated from the nuclear protein EBNA and
the virion protein BVRF1. The EBNA mimic shared with
CYP2D6, the hexameric—PAQPP—motif which is the core
region, is also shared between CYP2D6 and HSV-1. Despite
itshighdegreeofhomologywiththeself-epitope, theBVRF1
EBV peptide was totally unreactive in anti-CYP2D6 254–271
positive patients with AIH-2. The EBNA EBV mimic has
been found to be a speciﬁc target of antibody responses in
serum samples from patients with AIH-2 [135, 143].
The same group of investigators have also described a
case of a girl who developed anti-LKM1 following infection
at the time of liver transplantation (LT) for end-stage
alpha-1 antitrypsin deﬁciency-related cirrhosis [144]. The
girl developed overt de novo AIH eight years after LT.
T h i sg i r lh a db e e ne x p o s e dt oE B Va n dH S V - 1p r i o rt o
LT and acquired HCV and CMV infections subsequent to
LT [144]. Experiments investigating reactivity to virus/self-
mimicking sequences were performed in serum samples,
collected between 1989 and 2000. An in house ELISA was
used to assess cross-reactivity between CYP2D6 (252–271),
the key epitope of LKM1 reactivity, and its HCV, HSV-
1, CMV, and EBV viral homologues. Before LT, only an
IgG response to an HSV-1 mimic was present, while the
newly acquired CYP2D6252−271 response was accompanied
by reactivity to E1/HCV, CMV, and HSV mimics after LT
[144]. Reactivity to EBV mimic became detectable 2 months
after LT. Reactivity to CYP2D6252−271 was still present when
de novo AIH was diagnosed 8 years later. Identical LKM1
reactivity was detected eleven years after LT [144]. These
data supported the notion that a CYP2D6252−271 crossreac-
tive lymphocyte population, primed by HSV-1, underwent
expansion following exposure to mimicking sequences of
HCV, CMV, and EBV followed by production of LKM1 and
ultimately AIH development [144].
9. The Role of MolecularMimicrybetween
EBVandSelf inPBC
Several studies have demonstrated cross-reactivity between
microbial peptides and the major epitope in PBC, known
as PDC-E2 [131]. One study examined various microbial
sequences for similarity with PDC-E2 [131]. Sequence
similarity between the major human PDC-E2 autoepitopic




As mentioned, EBV antigens that could serve as targets
of cross-reactive antibodies speciﬁc for human PDC-E2 have
not been found [145]. However, other groups have examined
cross-reactivity between EBV sequences and sp100, the
major nuclear body autoantigen of PBC-speciﬁc anti-MND
antibody responses [146]. These antibodies are found in
approximately 30% of PBC patients, and those of theAdvances in Virology 7
IgG3 subclass have been associated with a more severe
disease progression [89]. Xie and Snyder [146]m a p p e d
epitopes which react with autoantibodies to sp100 (nuclear
dot). Immunoblotting demonstrated that 10 of 12 sera
recognized two major autoepitopes of approximately eight
amino acids long [146]. These two linear epitopes share
homology with several viral proteins which were found in
a database, including two fusion proteins containing EBV
protein sequences [146]. These sequences included the UL37
which shared homology with ND EI (epitope E1-V1), as well
as EBN4 and KITH which shared homologous regions with
ND EII (epitopes EII-V1 and V2, resp.) [146]. Intriguingly,
the UL37 and KITH sequences showed reactivity with sera
from patients with autoimmune disease [146]. These data
support the hypothesis that EBV may be involved in the
pathogenesis of autoimmune diseases with sp100, such as
some cases of PBC.
10.Autoimmune LiverDiseases,EBV,and
ImmuneDysregulation
As noted in the familial studies conducted by Vento et al. [20,
147], the two relatives who became infected with EBV and
HAV, and subsequently developed AIH, both had preexisting
ASGPR suppressor-inducer T-cell defects. This has led to the
hypothesis incorporating a genetic predisposition with viral
infection in the development of AIH [148]. In that theory,
an individual would have to have a genetic predisposition,
such as a particular HLA haplotype associated with AIH and
impairment of antigen-speciﬁc autoreactive regulatory cells
[148].InfectionwithHAVorHBVcouldleadtopersistentT-
and/or B-cell reactivity to liver-related autoantigens such as
ASGPRintheseindividuals,leadingtocytotoxicitytonormal
hepatocytes, and the development of AIH [148]. This theory
may also be applicable to other viral infections, with T-
and/orB-cellreactivitytoantigensseparatefromtheASGPR.
Several years later, it was demonstrated that a numerical and
functional dysregulation in CD4+ CD25+ T-regulatory cells
(Treg) is a feature in AIH patients [52–55]. Newly described
Th17 cells may also be involved, but their role is currently
not well deﬁned [45]. These studies clearly indicate that the




status of immunity speciﬁc for EBV has not been studied in
detail.
IPEX syndrome is a congenital disorder characterized
by immune dysregulation, caused by mutations in the
FOXP3 gene of the X chromosome, which is required for
the suppressive function of naturally arising CD4+ CD25+
regulatory T cells [150–152]. Defects in these pathways
are therefore capable of inducing autoimmunity. Patients
with IPEX syndrome are known to produce a variety of
autoantibodies including AMA [153]. Tsuda et al. report the
case of an 11-year-old male with IPEX, who was positive
for AMA, but with no clinical or biochemical evidence of
liver disease [153]. It is not known whether the AMA in
that case was directed against PDC-E2, and it is unknown
whether the child in that case eventually went on to develop
PBC [153]. Lucas et al. report the case of a child with
IPEX that developed EBV-induced lymphoma [154]. Those
authors note that immunosuppressive therapy can be used
to control autoimmune manifestations in patients with
IPEX [154]. The 3-month-old male IPEX patient in their
report was treated with rapamycin, which improved his
eczema, diarrhhoea, and aphthous stomatitis [154]. Eight
months after treatment, he presented with fever and tender
cervical lymphadenopathy, which was later diagnosed as B-
cell lymphoma with positive EBV testing [154]. These cases
highlight the possibility that EBV may induce autoimmunity
in genetically susceptible individuals, such as those with
IPEX syndrome. It is also possible that the immunological
dysregulation seen in these conditions may increase their
susceptibility to EBV infection.
A recent paper by Pender [155] presents a compelling
hypothesis involving immunological dysregulation, EBV
infection, and the development of autoimmunity. CD8+
T-cell deﬁciency is a characteristic of several autoimmune
diseases and also occurs in some relatives of patients
with autoimmune disease, suggesting an underlying genetic
susceptibility [155]. Pender suggests that the impairment
of CD8+ T cells results in the inability to control EBV
infection and thus there is accumulation of EBV-infected,
autoreactive B-cells in a variety of target organs, with clonal
expansion of these cells, and the development of ectopic
lymphoid follicles [155]. Within the target organ, the EBV-
infected autoreactive B cells would produce pathogenic
autoantibodies and provide costimulatory signals for the
survival of autoreactive T cells [155]. Pender also indicates
a role for vitamin D deﬁciency in this model [155]. As
vitamin D (and the vitamin D receptor) has been found
to be reduced in patients with autoimmune disease, and
reduced vitamin D is noted in higher latitudes which have
higher rates of autoimmune disease, a role for vitamin D
deﬁciency in autoimmunity is suspected. Pender suggests
that decreased vitamin D aggravates the deﬁciency in
CD8+ T cells, therefore causing further impairment of EBV
control [155]. Despite the need for extensive investigation,
this hypothesis highlights the intriguing interplay between
genetic susceptibility and infection which may play a role in
the development of autoimmune disease.
11. Conclusions
It appears that EBV has the potential to induce autoimmune
responses and indeed autoimmune disease. A wealth of
experimental data has been provided over the years in
various autoimmune diseases, mainly autoimmune rheuma-
tological conditions. However, the data obtained in autoim-
mune liver diseases are scarce and more work needs to
be done. Also, prospective studies are needed to investi-
gate whether EBV infection is causally related with the
development of extrahepatic autoimmune diseases such as
Sj¨ ogren’s syndrome, autoimmune thyroiditis, and rheuma-
toid arthritis, which frequently cooccur in patients with PBC
or AIH. As it stands, the thesis that EBV is strongly linked8 Advances in Virology









GWAS: Genome wide association studies
IBD: Inﬂammatory bowel disease
IDDM: Insulin dependent diabetes mellitus
MS: Multiple sclerosis
PBC: Primary biliary cirrhosis
PDC: Pyruvate dehydrogenase complex
PSC: Primary sclerosing cholangitis
RA: Rheumatoid arthritis
SjS: Sjogren’s syndrome
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